MRC Clinical Trials Unit at UCL
2nd Floor
90 High Holborn
London
WC1V 6LJ
Email: mrcctu.stampede@ucl.ac.uk
A five year follow-up of the STAMPEDE abiraterone comparison has been completed, and the results demonstrate that previously reported effects are robust. It shows that future results are unlikely to change meaningfully with further follow-up. The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy. For further details related to the follow-up results, please see this article published 12th April 2022 - https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018
STAMPEDE
MRC Clinical Trials Unit at UCL
2nd Floor
90 High Holborn
London
WC1V 6LJ
Email: mrcctu.stampede@ucl.ac.uk
STAMPEDE
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
See the latest News in STAMPEDE through the link to the right.